"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
| Descriptor ID |
D000951
|
| MeSH Number(s) |
D23.050.285
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in this website by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 5 | 3 | 8 |
| 1996 | 4 | 1 | 5 |
| 1997 | 4 | 1 | 5 |
| 1998 | 3 | 3 | 6 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 4 | 5 |
| 2001 | 3 | 4 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 1 | 5 | 6 |
| 2004 | 4 | 5 | 9 |
| 2005 | 7 | 2 | 9 |
| 2006 | 5 | 8 | 13 |
| 2007 | 1 | 6 | 7 |
| 2008 | 5 | 6 | 11 |
| 2009 | 8 | 4 | 12 |
| 2010 | 4 | 2 | 6 |
| 2011 | 3 | 0 | 3 |
| 2012 | 11 | 1 | 12 |
| 2013 | 5 | 9 | 14 |
| 2014 | 7 | 6 | 13 |
| 2015 | 0 | 8 | 8 |
| 2016 | 4 | 2 | 6 |
| 2017 | 4 | 3 | 7 |
| 2018 | 5 | 2 | 7 |
| 2019 | 5 | 2 | 7 |
| 2020 | 5 | 4 | 9 |
| 2021 | 4 | 3 | 7 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 3 | 4 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654.
-
Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia. Blood Adv. 2024 04 09; 8(7):1747-1759.
-
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024 Apr; 30(4):1013-1022.
-
Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. J Immunol. 2024 01 15; 212(2):188-198.
-
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine. Front Immunol. 2023; 14:1223331.
-
Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity. Biomaterials. 2023 11; 302:122334.
-
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023 03; 615(7953):697-704.
-
Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells. J Immunother Cancer. 2023 02; 11(2).
-
Non-viral precision T?cell receptor replacement for personalized cell therapy. Nature. 2023 03; 615(7953):687-696.